Literature DB >> 12635577

Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data.

Felicia C Allen-Ramey1, Phong T Duong, David C Goodman, Shiva G Sajjan, Linda M Nelsen, Nancy C Santanello, Leona E Markson.   

Abstract

We compared measures of treatment effectiveness when inhaled corticosteroids (ICSs) or leukotriene modifiers (LMs) were used as controller monotherapy for asthma. Asthma patients aged 6-55 years initiating ICS or LM monotherapy between July 1998 and June 1999 (index prescription) were identified using a managed care claims database. Asthma-related hospitalizations, emergency department (ED) visits, and use of short-acting beta-agonists and oral corticosteroids (OCSs) were assessed as proxies for treatment effectiveness. Propensity score was used to adjust for baseline differences between treatment cohorts. The change in the annual rate of claims from the preindex to postindex period for each measure was compared across treatment groups. Logistic regression models of the postindex composite events (hospitalization and/or ED) and OCS use were estimated. Nine hundred sixty patients were initiated on LMs (n = 153) and ICSs (n = 807). The mean annual rate of claims for OCSs increased in the ICS group (0.2) but was unchanged in the LM group (adjusted mean difference in change, 0.2; 95% CI, 0.05-0.4; p = 0.01). The mean annual rate of claims for short-acting beta-agonists increased in both the ICS and LM groups by 1.1 and 0.5, respectively (adjusted mean difference in change, 0.6; 95% CI, -0.06. 1.1; p = 0.08). Similar changes in annualized rates of claims for hospitalizations and ED visits were observed between treatment groups. In logistic regression models, greater odds of postindex OCS use was observed among the ICS group (odds ratio for ICS versus LM = 1.7; 95% CI, 1.04-2.8; p = 0.04). No association between treatment groups and postindex hospitalization and/or ED events was observed. In this managed care population, patients treated with ICSs or LMs had similar measures of treatment effectiveness, as measured by asthma-related health care resource use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12635577

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  7 in total

1.  Exploring robust methods for evaluating treatment and comparison groups in chronic care management programs.

Authors:  Aaron R Wells; Brent Hamar; Chastity Bradley; William M Gandy; Patricia L Harrison; James A Sidney; Carter R Coberley; Elizabeth Y Rula; James E Pope
Journal:  Popul Health Manag       Date:  2012-07-12       Impact factor: 2.459

Review 2.  Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.

Authors:  Bhupendrasinh F Chauhan; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

4.  Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring.

Authors:  Stanley Xu; Susan Shetterly; Andrea J Cook; Marsha A Raebel; Sunali Goonesekera; Azadeh Shoaibi; Jason Roy; Bruce Fireman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-02-15       Impact factor: 2.890

5.  Impact of asthma controller medications on clinical, economic, and patient-reported outcomes.

Authors:  Hiangkiat Tan; Chaitanya Sarawate; Joseph Singer; Kurt Elward; Rubin I Cohen; Brian A Smart; Michael F Busk; James Lustig; Jeana D O'Brien; Michael Schatz
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

6.  Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.

Authors:  Stanley Xu; Colleen Ross; Marsha A Raebel; Susan Shetterly; Christopher Blanchette; David Smith
Journal:  Value Health       Date:  2009-11-12       Impact factor: 5.725

Review 7.  Regulatory T cells mediated immunomodulation during asthma: a therapeutic standpoint.

Authors:  Mohammad Afzal Khan
Journal:  J Transl Med       Date:  2020-12-02       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.